
CAS 1402821-41-3
:Formule :C18H26N6OS
InChI :InChI=1S/C18H26N6OS/c1-4-8-24-11-20-15-16(19-9-14-7-6-12(3)26-14)22-18(23-17(15)24)21-13(5-2)10-25/h6-7,11,13,25H,4-5,8-10H2,1-3H3,(H2,19,21,22,23)/t13-/m1/s1
Code InChI :DPTXJOUVBMUSGY-CYBMUJFWSA-N
SMILES :CCCN1C=NC2=C(N=C(N=C21)N[C@H](CC)CO)NCC3=CC=C(S3)C
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
6 produits trouvés.
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
GV-58
CAS :GV-58 agonizes N/P-Q-type Ca2+ channels (EC50: 7.21/8.81 μM) with 20x less inhibition on CDK kinases.Formule :C18H26N6OSDegré de pureté :97.36%Couleur et forme :Yellow SolidMasse moléculaire :374.504(R)-2-((6-(((5-Methylthiophen-2-yl)methyl)amino)-9-propyl-9H-purin-2-yl)amino)butan-1-ol
CAS :Formule :C18H26N6OSDegré de pureté :%Masse moléculaire :374.5036(R)-2-((6-(((5-Methylthiophen-2-yl)methyl)amino)-9-propyl-9H-purin-2-yl)amino)butan-1-ol
CAS :Degré de pureté :98+%Couleur et forme :SolidMasse moléculaire :374.5100098GV-58
CAS :GV-58 is a molecule that has been shown to have physiological levels in the brain. GV-58 is an active analog of a neurotransmitter and has been shown to disrupt physiological levels of neurotransmission. GV-58 has also been shown to cause symptoms such as spontaneous activity, disrupted sleep cycles, and spontaneous physical activity. This drug has also been shown to be effective against cancer cells in culture and animal models. More research is needed to determine if this drug is safe for use in humans.Formule :C18H26N6OSDegré de pureté :Min. 95%Masse moléculaire :374.5 g/mol






